Brain expert: Why I jumped ship to Google Silicon Valley offers a fresh way to tackle conditions such as schizophrenia says US mental-health expert Thomas Insel The New Scientist By Sally Adee Nov 4, 2015 Why did you leave the National Institute of Mental Health to work for Google? I have to confess that after […]
These are some links to articles I’ve reviewed in the recent past – industry funded, professionally-ghost-written, clinical trials of the newer atypical antipsychotics published in highly ranked, peer reviewed, academic journals. There are some other things they share in common [I made it easy with my red highlighting]: Lurasidone in the treatment of schizophrenia: a […]
Four years ago, shortly after it became apparent that PHARMA was exiting CNS drug development en mass, there was a new Atypical Antipsychotic approved by the FDA for Schizophrenia – Lurasidone [Latuda®]. Since my interest in the FDA and the psychoactive drugs had come after all the previous approvals, I had never gotten in on […]
I should’ve just let things lie with my last post – stuck with my bit of sarcasm and moved on. Instead, I clicked on the link that lead to Fusion‘s interview of Dr. Insel, and it wound me up all over again. I’ve characterized Dr. Insel as a breakthrough·freak…– moving from one shiny object to […]
Google’s Latest Hire Has a Creepy Plan to Track Your Mental Health GIZMODO by Annalee Newitz 10/27/15 Google’s parent company Alphabet has just hired Thomas Insel, the former head of the National Institute of Mental Health, who has some pretty weird ideas about what his new job will entail. Insel told a crowd at Chicago […]
While it is not fashionable to talk of psychoanalysis or other mind theories these days, I can think of no other way to approach this editorial by the editor of the New England Journal supporting Robert Califf’s nomination for the leadership of the FDA. And the particular mind theory isn’t really psychoanalytic, it’s just what’s […]
I have no real information about Ketamine as a treatment for depression, though it does seem beyond peculiar to be writing about a club drug in the context of treating a mental illness. But I’m writing about it for another reason nonetheless – a ethical reason. As common as it has become, I protest peer […]
Below is a collection of references to everything you might want to know about Dr. R. K. Chandra, a Canadian researcher whose 1989 paper, Influence of maternal diet during lactation and use of formula feeds on development of atopic eczema in high risk infants, was retracted by the BMJ yesterday. It was originally published by […]
On has to be awed by blogger Neuroskeptic whose scope far exceeds the rest of us combined. Here, he clears up the dilemma I obsessed about recently. When the results of the RAISE study were published a few days ago, the extensive press coverage proclaimed that the NAVIGATE [NAV] patients received a much lower dose […]
A month ago, I wrote about a woman who had arrived in our clinic on a remarkable regimen if medications [blitzed…]. To repeat: She was brought to the clinic by her aunt who was taking care of her temporarily. She was a woman in her fifties with a cast on her lower leg from a […]